Anixa Biosciences (ANIX) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 42.9% versus a loss of 34.5%. Over five years, ANIX leads with a -33.7% price change compared with -97.8% for PYPD. Anixa Biosciences is the larger company by market cap ($101.2 million vs $99.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | PYPD |
|---|---|---|
| Share price | $2.91 | $4.90 |
| Market cap | $101.16M | $99.53M |
| 1-day change | -1.36% | -1.01% |
| YTD return | -6.73% | +12.90% |
| 1-year return | -34.46% | +42.86% |
| 5-year return | -33.71% | -97.83% |
| EPS (TTM) | $-0.32 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $5.73 |
| 52-week low | $2.32 | $3.06 |
| Distance from 52-week high | -46.70% | -14.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +235.05% | +139.80% |
| Average volume | 302.95K | 176.73K |
| Shares outstanding | 34.76M | 20.31M |
| Employees | 4 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed ANIX by 77.3 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Healthcare · Biotechnology · 69 employees
ANIX vs PYPD FAQ
Which is bigger, Anixa Biosciences or PolyPid?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $101.16M compared with $99.53M for PolyPid (PYPD).
Which stock has performed better over the past year, ANIX or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -34.46% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and PolyPid in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.